Key Takeaways:
GeneDx Holdings Corp. faces a securities class action after the genetic testing company's stock lost $33.42 a share, or 49 percent, on May 5 following a disastrous first-quarter earnings report that revealed a $31.3 million impairment tied to its Fabric Genomics acquisition.
"The company's statements about Fabric's viability and the acquisition's revenue potential were materially false and misleading," the complaint alleges. The lawsuit, filed in US District Court for the District of Connecticut, seeks to represent investors who bought GeneDx common stock between April 16, 2025 and May 4, 2026.
GeneDx acquired Fabric Genomics, an AI-driven genomic interpretation firm, in April 2025 for up to $51 million, including $33 million in cash upfront. At the time, management touted the deal as one that would "expand GeneDx's addressable market with several scalable revenue streams" and transform "static data into a dynamic, recurring revenue-generating platform." The impairment loss of $31.3 million — equal to 94 percent of the upfront cash payment — was disclosed in the company's Q1 2026 results on May 4.
The earnings report also showed adjusted gross margin falling to 69 percent from 74 percent a year earlier, with GeneDx missing revenue estimates for both its exome and genome testing lines. The company slashed its full-year 2026 revenue guidance to a range of $475 million to $490 million, down from a prior forecast of $540 million to $550 million.
Investors have until Aug. 3 to file for lead plaintiff status in the case, captioned Taher Basma v. GeneDx Holdings Corp., No. 26-cv-00880. Multiple law firms, including Hagens Berman, Kessler Topaz Meltzer & Check, and Kahn Swick & Foti, have announced investigations or filed complaints on behalf of shareholders.
The 49 percent single-day decline erased billions in market value and leaves GeneDx trading near its lowest levels since the Fabric deal was announced. The company's next catalyst will be its Q2 2026 earnings report, where investors will look for signs of stabilization in reimbursement rates and gross margins.
This article is for informational purposes only and does not constitute investment advice.
